Biogen has turned to M&A to offset its recent troubles with pipeline failures and aborted product launches, agreeing to a $7.3 billion deal to acquire Reata Pharma.
Bristol-Myers Squibb is facing some serious near-term challenges as its top-selling drugs come under pressure, forcing it to slash its sales forecasts for the year.
Pfizer's longstanding dominance of the pneumococcal vaccines category could be threatened by Merck & Co, which has just reported new data on its V116 shot in older adu
Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance has been approved for chronic kidney disease in the EU - the first major market to clear the new use for the
High-profile digital health investor Luba Greenwood recently announced that she’s joined as Chair of the Board at Closed Loop Medicine, a company applying machine learning to precision drug